Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

15.62
-0.5700-3.52%
Pre-market: 15.30-0.3200-2.05%09:21 EST
Volume:1.93M
Turnover:29.97M
Market Cap:2.53B
PE:-4.31
High:16.01
Open:15.72
Low:15.10
Close:16.19
52wk High:25.00
52wk Low:6.36
Shares:162.00M
Float Shares:152.00M
Volume Ratio:0.92
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6224
EPS(LYR):-3.3716
ROE:-60.66%
ROA:-34.32%
PB:3.66
PE(LYR):-4.63

Loading ...

Dyne Therapeutics reports $791.9 million cash position as of September 30, 2025

Reuters
·
Nov 06, 2025

Dyne Therapeutics Q3 Basic EPS USD -0.76

THOMSON REUTERS
·
Nov 06, 2025

Dyne Therapeutics Q3 EPS USD -0.76 VS. Ibes Estimate USD -0.84

THOMSON REUTERS
·
Nov 06, 2025

Dyne Therapeutics Inc: Reaffirming Expected Cash Runway Into Q3 2027

THOMSON REUTERS
·
Nov 06, 2025

Dyne Therapeutics Inc : JP Morgan Raises Target Price to $18 From $9

THOMSON REUTERS
·
Nov 05, 2025

Dyne Therapeutics to Present at Evercore Healthcare Conference

Reuters
·
Nov 03, 2025

This biotech's stock soared as investors look for the next buyout target

Dow Jones
·
Oct 28, 2025

Small U.S. Stocks End Mixed As Dyne Therapeutics Leads, Intellia Therapeutics Lags

Dow Jones
·
Oct 28, 2025

Dyne Therapeutics Shares Rise After Novartis Reaches Deal to Buy Avidity

Dow Jones
·
Oct 28, 2025

BUZZ-U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm

Reuters
·
Oct 28, 2025

BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity

Reuters
·
Oct 27, 2025

Dyne Therapeutics rises 42.4%

TIPRANKS
·
Oct 27, 2025

Stifel Nicolaus Keeps Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Oct 27, 2025

Dyne Therapeutics Faces Overhang Ahead of Data Readout, Oppenheimer Says

MT Newswires Live
·
Oct 10, 2025

Dyne Therapeutics, Inc. : Oppenheimer Cuts to Perform From Outperform

THOMSON REUTERS
·
Oct 10, 2025

Dyne Therapeutics downgraded to Perform at Oppenheimer following additional data

TIPRANKS
·
Oct 10, 2025

Dyne Therapeutics Announces Positive One-Year Phase 1/2 Data for Zeleciment Basivarsen Demonstrating Functional Improvement in Myotonic Dystrophy Type 1

Reuters
·
Oct 07, 2025

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement From Phase 1/2 Achieve Trial of Zeleciment Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1)

THOMSON REUTERS
·
Oct 07, 2025

A Fresh Look at Dyne Therapeutics (DYN) Valuation Following Japan Orphan Drug Win and Board Addition

Simply Wall St.
·
Oct 06, 2025

Dyne Therapeutics Elects Brian Posner to Board

TIPRANKS
·
Oct 03, 2025